Rxsight Inc
NASDAQ:RXST

Watchlist Manager
Rxsight Inc Logo
Rxsight Inc
NASDAQ:RXST
Watchlist
Price: 30.72 USD -8.11% Market Closed
Market Cap: 1.2B USD

Rxsight Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Rxsight Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Rxsight Inc
NASDAQ:RXST
Net Issuance of Common Stock
$106m
CAGR 3-Years
363%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Haemonetics Corp
NYSE:HAE
Net Issuance of Common Stock
-$67.3m
CAGR 3-Years
N/A
CAGR 5-Years
19%
CAGR 10-Years
-14%
ICU Medical Inc
NASDAQ:ICUI
Net Issuance of Common Stock
$5.9m
CAGR 3-Years
-20%
CAGR 5-Years
7%
CAGR 10-Years
-13%
Align Technology Inc
NASDAQ:ALGN
Net Issuance of Common Stock
-$423.3m
CAGR 3-Years
-19%
CAGR 5-Years
-5%
CAGR 10-Years
-23%
Lantheus Holdings Inc
NASDAQ:LNTH
Net Issuance of Common Stock
$7.6m
CAGR 3-Years
12%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Merit Medical Systems Inc
NASDAQ:MMSI
Net Issuance of Common Stock
$19.6m
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
12%

Rxsight Inc
Glance View

Market Cap
1.2B USD
Industry
Health Care

In the dynamic realm of ophthalmology, RxSight Inc. has carved a niche as a pioneering force in enhancing vision outcomes for cataract patients. At the heart of the company’s innovation is its Light Adjustable Lens (LAL) system. Traditional intraocular lenses (IOLs), once implanted, lock patients into a certain prescription, accepting only minimal adjustments. RxSight, with its groundbreaking technology, offers a solution that breaks this convention. Post-cataract surgery, the LAL allows ophthalmologists to precisely adjust the lens prescription using UV light, often yielding better visual acuity tailored to patient needs. This transformative approach turns the one-size-fits-all model of vision correction into a personalized patient experience, promising a brighter, clearer outlook on life. Commercially, RxSight operates within the medical device industry, focusing on capturing a significant share of the cataract surgery market—one of the most frequent surgeries performed worldwide. The company earns revenue primarily through the sale of its LAL system to eye care professionals and clinics. This business model is akin to a razor-and-blade approach; besides the initial sale of the adjustable lenses, RxSight garners continuous revenue from associated products and services, such as the light delivery device and follow-up adjustments required post-surgery. By addressing a substantial unmet need with a recurring revenue stream, RxSight strategically positions itself for growth within the burgeoning biotech sector, all while setting new benchmarks for patient satisfaction in eye care.

RXST Intrinsic Value
14.26 USD
Overvaluation 54%
Intrinsic Value
Price

See Also

What is Rxsight Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
106m USD

Based on the financial report for Dec 31, 2023, Rxsight Inc's Net Issuance of Common Stock amounts to 106m USD.

What is Rxsight Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
363%

Over the last year, the Net Issuance of Common Stock growth was 1 253%. The average annual Net Issuance of Common Stock growth rates for Rxsight Inc have been 363% over the past three years .

Back to Top